

Ceritinib ASCEND-4

PRELIMINARY SCORE

CURATIVE




NON-CURATIVE



ADJUSTMENTS

Quality of life



Delayed deterioration in global QoL

Serious and disabling adverse effects



Other adjustments



Ceritinib ASCEND-4

SCORE

CURATIVE



Overall Survival / Disease-Free Survival / Pathological Complete Response

NON-CURATIVE




Overall Survival



Progression-Free Survival



Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate



Overall Response Rate / Duration of Response

Overall Survival / Disease-Free Survival / Pathological Complete Response

INFORMATION

Tumour type: Thoracic Malignancies
Therapeutic Indication: First-line treatment of adult patients with anaplastic lymphoma kinase (ALK) positive advanced non small cell lung cancer (NSCLC) stage IIIB/IV
Experimental Arm: Ceritinib
Control Arm: Chemotherapy



